-
Jun. 30, 2025SanegeneBio Announces First Patient Dosed in Phase I trial of CFB-Targeting siRNA Drug for Complement-Mediated DiseasesMore
-
May 20, 2025SanegeneBio's siRNA Drug Targeting CFB Receives Clinical Trial Approval from the NMPA for Complement-Mediated DiseasesMore
-
Mar. 07, 2025SanegeneBio Announces the Initiation of Phase II Clinical Trials for the siRNA Drug SGB-9768 Targeting C3More
